Epidemiology of chronic kidney disease in cancer patients: Lessons from the IRMA study group

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 548-556

  Launay Vacher, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Dosage adjustment; Kidney disease; Nephrotoxicity; Prevalence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CREATININE; DRUG METABOLITE; IBANDRONIC ACID; OXALIPLATIN; PAMIDRONIC ACID; SUNITINIB; ZOLEDRONIC ACID;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TRANSFORMATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIVER METABOLISM; MALIGNANT NEOPLASTIC DISEASE; NEPHRECTOMY; NEPHROTOXICITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; SURVIVAL RATE; SURVIVAL TIME; URINARY EXCRETION;

EID: 78649917189     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.003     Document Type: Article

References (28)

1. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
2. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
3. Froissart M., Rossert J., Jacquot C., Paillard M., Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763-773.
4. Holweger K., Lipp H.P., Dietz K., Hartmann J.T., Bokemeyer C. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 2008, 42:1749-1757.
5. Kleber M., Cybulla M., Bauchmüller K., Ihorst G., Koch B., Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007, 18:950-958.
6. Launay-Vacher V., Chatelut E., Lichtman S.M., Wildiers H., Steer C., et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321. International Society of Geriatric Oncology.
7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(Suppl 1):S1-S266. National Kidney Foundation.
8. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
9. Launay-Vacher V., Oudard S., Janus N., Gligorov J., Pourrat X., Rixe O., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007, 110:1376-1384. Renal Insufficiency and Cancer Medications (IRMA) Study Group.
10. Janus N., Oudard S., Beuzeboc P., Gligorov J., Ray-Coquard I., Morere J., et al. Prevalence of renal insufficiency in cancer patients: data from the IRMA-2 study [abstract]. J Clin Oncol 2009, 27(Suppl):15s.
11. Huang W.C., Levey A.S., Serio A.M., Snyder M., Vickers A.J., Raj G.V., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735-740.
12. Wong G., Hayen A., Chapman J.R., Webster A.C., Wang J.J., Mitchell P., et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009, 20:1341-1350.
13. Launay-Vacher V., Janus N., Spano J., Gligorov J., Ray-Coquard I., Beuzeboc P., et al. Impact of renal insufficiency on cancer survival: results of the IRMA-2 study [abstract]. J Clin Oncol 2009, 27(Suppl):15s.
14. Maher J.F. Pharmacokinetics in patients with renal failure. Clin Nephrol 1984, 21:39-46.
15. Launay-Vacher V., Storme T., Izzedine H., Deray G. [Pharmacokinetic changes in renal failure]. Presse Med 2001, 30:597-604.
16. Craig R.M., Murphy P., Gibson T.P., Quintanilla A., Chao G.C., Cochrane C., et al. Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure. J Lab Clin Med 1983, 101:496-506.
17. Leblond F.A., Petrucci M., Dubé P., Bernier G., Bonnardeaux A., Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2002, 13:1579-1585.
18. Khosravan R., Toh M., Garrett M., La Fargue J., Ni G., Marbury T.C., et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010, 50:472-481.
19. Henderson S.J., Lindup W.E. Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin. Biochem Pharmacol 1990, 40:2543-2548.
20. Henderson S.J., Lindup W.E. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 1992, 263:54-60.
21. Bowmer C.J., Lindup W.E. Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharmacol 1982, 31:319-323.
22. Dreisbach A.W. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 2009, 86:553-556.
23. Nolin T.D., Naud J., Leblond F.A., Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008, 83:898-903.
24. Kintzel P.E., Dorr R.T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995, 21:33-64.
25. Lichtman S.M., Wildiers H., Launay-Vacher V., Steer C., Chatelut E., Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007, 43:14-34.
26. Launay-Vacher V., Karie S., Deray G. GPR Anticancéreux. Guide de prescription des medicaments chez le patient insuffisant rénal 2009, Meditions International, Paris. 4th ed.
27. Aronoff G.R., Bennett W.M., Berns J.S., Brier M.E. Drug prescribing in renal failure: dosing guidelines for adults 2007, American College of Physicians, Philadelphia. 5th ed.
28. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008, 61:903-909. European Society of Clinical Pharmacy Special Interest Group on Cancer Care.